Pharma BD Deal Intelligence
CIMA's OraVescent tech delivered Fentora, but safety scandals, an off-label marketing felony/settlement in the same product family, and eventual full wind-down of the CIMA entity by acquirer Teva mark this as a modest, troubled outcome rather than a clear win.
Full analysis, sources & comparables →CEO Frank Baldino: 'Combining CIMA's innovative delivery technologies together with our clinical development, regulatory, and sales and marketing experience,…
Baldino: the deal 'provides us with a tremendous opportunity to significantly expand our established pain care franchise by adding OraVescent fentanyl to our…
Final FTC decision and order formalizes the Barr generic Actiq license remedy and permits Cephalon's CIMA acquisition to fully close.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
FTC consent agreement Aug 9 2004; required licensing of Actiq generic to Barr; oral disintegrating tablet tech
CIMA's OraVescent tech delivered Fentora, but safety scandals, an off-label marketing felony/settlement in the same product family, and eventual full wind-down of the CIMA entity by acquirer Teva mark this as a modest, troubled outcome rather than a clear win.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Cephalon Inc. / CIMA Labs Inc. (this deal) | 2004 | $515M | 46 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Cephalon Inc. / Salmedix, Inc. | 2005 | $160M | 89 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
| Cephalon Inc. / Cell Therapeutics, Inc. | 2005 | $70M | 74 |
| Cephalon Inc. / Anesta Corp. | 2001 | $444M | 65 |
| Cephalon Inc. / Anesta Corp. | 2000 | $444M | 64 |
← Browse all deals · How we score deals
More: 2004 deals · Cephalon Inc. deals · Oncology deals